Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
EMERYVILLE, Calif., Nov. 15, 2016 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Piper Jaffray Healthcare Conference in New York on Tuesday, November 29, 2016 at 9:30 a.m. Eastern Time.
The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available for approximately two weeks.
About Adamas Pharmaceuticals, Inc.
Adamas is a pharmaceutical company that is developing new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and epilepsy. Adamas has pioneered a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve symptomatic relief without additional tolerability issues. We have developed a portfolio of chrono-synchronous therapies to potentially address chronic neurologic disorders. Our lead program, ADS-5102 in development for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, is currently being evaluated by the U.S. Food and Drug Administration (FDA) for potential approval in 2017. ADS-5102 has additional opportunities to potentially provide symptomatic treatment of other chronic neurologic disorders such as multiple sclerosis walking impairment and several other indications. Our newest clinical development program, ADS-4101, is entering the clinic for the improved control of epileptic seizures. Additionally, through our license agreement with Forest Laboratories Holding Ltd. (a wholly owned subsidiary of Allergan plc), the company is eligible to receive royalties on sales of NAMENDA XR® and NAMZARIC® beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are registered trademarks of Merz Pharma GmbH & Co. KGaA.
Martin Forrest VP Corporate Communications and Investor Relations 510-450-3528
